NSE: AJANTPHARM | BSE: 532331

Mid-range Performer

Download real time

2431.90 7.20 (0.30%)

Near 52W Low of ₹2327.30

5,718 NSE+BSE Volume

NSE 30 Sep, 2025 9:43 AM (IST)

30,377.4

Market Cap

High in industry

0.7

Beta 1Year

Very Low volatility

Ajanta Pharma Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for AJANTPHARM, BSE:532331 Ajanta Pharma Ltd.

Ajanta Pharma Ltd.

27 Feb 2020

2431.90

0.30%

Earnings back on track after bottoming out in FY19

Buy: Ajanta Pharma Ltd.

Target

Motilal Oswal

With stability in industry cash cycle, AJP has enhanced its business scope in the branded markets of Asia and Africa. For branded generics business (67% of sales), AJP has guided for 9- 11% YoY growth for the next three years. Covered market growth in Dermatology for the past five years was 16%, while AJP grew at 8% due to a high base of Melacare range of products and higher attrition in MRs. Going forward, covered market growth is expected to be 9- 10%. Compared to its subdued growth in the past, AJP expects to do better (11- 12%) as (a) MR team being stabilized for this segment, (b) renewed interest in Melacare range of products and (c) new launches lined up in this segment. Considering covered market growth expectation at 7-8%, AJP intends to do better than industry at 10-11% in Cardiology.

Number of FII/FPI investors decreased from 385 to 371 in Jun 2025 qtr

Ajanta Pharma Ltd.

06 Feb 2020

2431.90

0.30%

Ajanta Pharmaceuticals

Buy: Ajanta Pharma Ltd.

Target

ICICI Securities Limited

Domestic formulations comprise 33% of FY19 revenues. The main distinguishing factor is the uncanny knack of launching maximum number of first time launches with focus on new drug delivery system (NDDS). Out of 270+ actively marketed brands, ~60% were first time launches. However, a slowdown in dermatology segment due to increased competition in existing products and slow offtake in new launches are some near term challenges. We expect domestic formulations to grow at ~12% CAGR in...

Ajanta Pharma Ltd. is trading below all available SMAs

Ajanta Pharma Ltd.

07 Nov 2019

2431.90

0.30%

Ajanta Pharmaceuticals

Buy: Ajanta Pharma Ltd.

Recommendation Target

ICICI Securities Limited

Prabhudas Lilladhar released a Buy report for Ajanta Pharma Ltd. with a price target of 3200.0 on 19 Sep, 2025.

Ajanta Pharma Ltd.

06 Nov 2019

2431.90

0.30%

Ajanta Pharma - 2QFY20 Result Update

Ajanta Pharma Ltd.

Reliance Securities

Ajanta Pharma Ltd. is trading below all available SMAs

Ajanta Pharma Ltd.

06 Aug 2019

2431.90

0.30%

Ajanta Pharma Ltd. - Result Update - 06 August 2019

Results Update: Ajanta Pharma Ltd.

Way2Wealth

Ajanta reported growth across most of the financial line items YoY and QoQ. Revenue/EBITDA/PAT grew by 20%/7%/9%YoY, while sequentially it grew by 19%/32%/30%. However, gross and EBITDA margins declined 700bps and 335bps YoY....

Ajanta Pharma Ltd. is trading below all available SMAs

Ajanta Pharma Ltd.

01 Aug 2019

2431.90

0.30%

Ajanta Pharma - 1QFY20 Result Update

Ajanta Pharma Ltd.

Reliance Securities

Ajanta Pharma Ltd. is trading below all available SMAs

Ajanta Pharma Ltd.

01 Aug 2019

2431.90

0.30%

Ajanta Pharmaceuticals

Hold: Ajanta Pharma Ltd.

Target

ICICI Securities Limited

Domestic formulations - Focus on new launches, few therapies Domestic formulations comprise 33% of FY19 revenues. The main distinguishing factor is the uncanny knack of launching maximum number of first time launches with focus on new drug delivery system (NDDS). Out of 270+ actively marketed brands, ~60% were first time launches. However, a slowdown in dermatology segment due to increased competition in existing products and slow offtake in new launches are some near term challenges. We expect domestic formulations to grow at ~12% CAGR in...

Prabhudas Lilladhar released a Buy report for Ajanta Pharma Ltd. with a price target of 3200.0 on 19 Sep, 2025.

Ajanta Pharma Ltd.

02 May 2019

2431.90

0.30%

Ajanta Pharmaceuticals

Hold: Ajanta Pharma Ltd.

Target

ICICI Securities Limited

Domestic formulations comprise 33% of FY19 revenues. The main distinguishing factor is the uncanny knack of launching maximum number of first time launches with focus on new drug delivery system (NDDS). Out of 270+ actively marketed brands, ~60% were first time launches. However, a slowdown in the dermatology segment due to increased competition in existing products and slow offtake in new launches may impact near term...

Promoters pledged 1.51% of shares in last quarter. Total pledge stands at 14.12% of promoter holdings

Ajanta Pharma Ltd.

01 May 2019

2431.90

0.30%

Africa/institutional anti-malaria drag performance???

Buy: Ajanta Pharma Ltd.

Target

Motilal Oswal

1 May 2019 Revenue declined 3% YoY to INR5.1b (in-line) in 4QFY19, largely on account of the weakness in (a) institutional anti-malaria (-26% YoY; 9% of sales) and (b) Africa branded generic (-31% YoY; 15% of sales) businesses. However, the impact was partly mitigated by the ramp-up in US sales (+79% YoY; 15% of sales) and steady growth in the India business (+8% YoY; 30% of sales)/Asia (+9% YoY; 28% of sales). EBITDA margin, too, contracted 164bp YoY to 24.7% (our v/s 19.8% in the year-ago period) and RM cost. Other expenses, however, declined to 34% of sales (36.2% in 4QFY18), providing some comfort to the FY19, sales/EBITDA/PAT declined 4%/14%/17% YoY to INR20.5b/INR5.6b/INR3.8b. In FY19, AJP filed 13 and received 12 ANDA approvals (including two tentative approvals). The company has commercialized 25 ANDAs till date.

Promoters pledged 1.51% of shares in last quarter. Total pledge stands at 14.12% of promoter holdings

Ajanta Pharma Ltd.

01 Feb 2019

2431.90

0.30%

Ajanta Pharmaceuticals

Hold: Ajanta Pharma Ltd.

Recommendation Target

ICICI Securities Limited

Ajanta Pharma's Q3FY19 results were below I-direct estimates on all fronts mainly due to lower-than-exacted export formulation sales Revenues declined 17.4% YoY to | 485.1 crore (I-direct estimate: | 522.6 crore) due to 26.7% YoY decline in export formulations to...

Prabhudas Lilladhar released a Buy report for Ajanta Pharma Ltd. with a price target of 3200.0 on 19 Sep, 2025.

Is Ajanta Pharma Ltd. worth buying?

189 Votes:

Buy 77.25%

Sell 15.87%

Hold 6.88%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf